This report was first published by Endpoints News. To see the original version, click here
GSK shared early promising data Sunday from the antibody-drug conjugate it licensed from its Chinese partner Hansoh Pharma. The UK company now plans to start studying the asset in five Phase 3 studies in gynecological cancers.
The antibody-drug conjugate, known as mocertatug rezetecan (or mo-rez), targets an immune checkpoint protein called B7-H4. GSK licensed the drug from Hansoh Pharma in 2023 as part of a deal worth up to $1.49 billion, one of a growing number of pharma companies turning to Chinese drug developers for new assets.
您已阅读18%（627字），剩余82%（2849字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。